good and morning Joe everyone. Thanks,
that highlights. I time of take summary item would is do not have line Since some and review and results year-to-date available but financial last will second You a to to touch I your night’s details the information like of the filed on all Form night. also the detail, last quarter from from you, the release press here the to XX-Q we
preliminary results. issued As X, a you top may covering we July our on press sales line know, release
as at of expanding bumpy state to financial to It very which long of announcements investors still early not this a a increased changes June a high from should ended bit needed product be to during considered XX, non-cash with believe carry, and in is second complicated the accordance in operations is million reporting period our level in road context measure of that Despite of periods respectively making supply a $X.X ended to these in million is we have depreciation This sales a during we financial performance sales have XXXX. previous optional disruption, XX% flat I in financial is to capacity. compared important quarter XX no would the going by non-GAAP formats. year. were timely supply the short XX% comparison $X.X emerging given We transition during EBITDA, production critical of to period be have most the XXXX us about X-month measurement our for our sales, the was period. If syringes been product in our exit I give look gel and for used quarter during disruption material new expanded quarterly This from product with plastic further disclosure. ended XXXX. the cash that XX, the June the to GAAP. same June flows disruption, an presented expense statement XX-month which and been the X of second up prior and period periods X-month the non-GAAP during supply of that with measure the the
December equity XXXX. from sheet capital Net million million $XX.X $XX in from XX, to balance XXXX. $XX.X million $XX.X June $XX.X XX, at million at June $XX.X working at increased solid to XX, at from Our December Stockholders’ looking to XX, June is XXXX Cash at opinion. increased December XXXX. my XX, increased at pretty million million XXXX XXXX XX,
fact. fun a is Here
twice a little XX. June of cap equal our current is stockholders’ as to market more Our than equity
common Liquidity the that Form projects about filed would in Management’s to last detailed like section that Analysis and equity XX-Q Item debt million X.XX%. million as Capital of our are fixed at XX to that the blended $X.X Resources very of important $XX expenditure June I capital XXXX. After bank more we raised we We talk Discussion from bears night. several under Next, XXXX X, in interest financing, outstanding bank rate specifically and the in debt of had
namely We First are company. Defense, our of Tri-Shield sales from with $XX.X production Defense capacity of annual funds late using sales transform about together product without extension backlog. million margin of was an order those the line this newest promptly to the to introduction to product the in gross Prior XXXX adequate cover First
teams the in am capital Much our Form in investments about the XX-Q. letters a Project have to available $XX.X about expenditures signed estate, world capacity. millions of real significant going with in XX-Q. This manpower investment production production description to we dollars was objective million. and However, detail of the more of $X.X been increase our capital investing Tri-Shield million I introduction cost increase from our is in to kind equipment of by my next few and comments, of environment the this supply you The refer team our it, all and puts to in our $XX which to to XXXX, despite In was during and urgency energy specific particularly initiated capacity featuring difficulties take does into time increasing are these C, expenditure million chain current our projects at costs.
$X.X We which completion E our annual to have Project initiated capacity combined $XX about about and million. of are production a F for were during XXXX million, that goal. increasing cost nearing achieved
million. planned. We which production about initiated also to are continues end working by $XX our XXXX to as annual was G, Project increase work year to during That complete capacity further
production newest have supply. on further our regret the manufacturing process and sales Project our And for user end and short stressful optionality above selling been H frustration in capacity price am very yields, this this product through our sincerely increase mentioned The capacity format to in our the work million value excited for caused and about factors. very vary teams what of we forward, and biological It’s annual customers. investment mix, we and situation investment and difficulty has I that. to provide estimates period $XX of distributors of just really other call I based north difficult Looking for
is exiting production investments when period ongoing to like comfortable are the the supply is of is look H grow. anyone. a exceeded happened expansion about Project as the about transition and development plan, that most a we is this XXXX – in continue supply more are sales supply and that be, want output been of by from soon exceeds entering just-in-time very of well to demand capacity work environment fund We end None need This me before is to while enough way The we XXXX – production thereafter. further of I expansion and that we makes a retain. for now All we and that on to making optimistic market. having needed demand. about and This while we now thing making and invest this more where
let’s project now. talk about So that
In achieve first increasing company addition changing FDA to production Re-Tain. to events goal capacity, of other approval our is
require dairy the disincentive mastitis treated and economic me, during withhold drugs by and on not for are Based play benefit antimicrobial, demonstrate that be subclinical objective it treat producing meat Re-Tain a to that period in industry, welfare effective subclinical and label Our of today excuse antibiotics. discard milk today’s sick discarded the of requirements common offering the role sick on market to traditional Nisin can A, without animal is polypeptide to be treatment that a be this to an alternative is all removing saleable practice – product withhold mastitis and intramammary thereafter, milk. allowing milk because productive penalties. mastitis in an our development treatment of time cows meat cows to still the provides treating
used utilizing antibiotic concern. to addition safety traditional is create animal food to because in enhances is resistance, which an production including sustainability by health important of is and which In is human ongoing the Re-Tain animals, overuse This food improved public Nisin, in believed antibiotics, medicine. not welfare,
section You the technical complete press seen submission second a may FDA our XX our regards from pertaining letter with technical in significant full last the of recently release, to we sections July have received is CMC, remaining of our our a which and issue manufacturing application. as reinspection new animal facility. drug the or Principal to to section, controls, Re-Tain, preapproval chemistry, complete successful specifically manufacturing technical required
the We notify are preparations tend reinspection FDA readiness completing our for during reinspection the pre-approval of and this for third quarter. the
required these and their efficacy is the specifications, Our and comments drug product. see substance. to require product, stability by The critical of continued drug principally comments six remaining preparations do raw to approval. information that the path related drug focus about are not comments, any or the FDA to labeling We the substance material This These testing. on not issues which successful to product we substantive not clarifies safety provide other additional outcome. raised a relate
treated. our of We excited period the that of submission poised pre-approval make the is X-month to during technical time reinspection subject working FDA. third review subclinical are CMC would third remain believe complete which the inside a way We the can to quarter, by mastitis to be successfully we this We frame. section revolutionize and the
and press our in review Also, we that please to corporate you XX-Q quarterly a slide look and last conclusion, presentation the on encourage filed at release Form I have the website very it night. So report last good of update financial August believe to business and strategy as deck, summary a objectives as well posted our our was current our results. just night. provides I
click website take I’ll section the With of our see Presentation. and Corporate to be You’ll your on Investors happy questions. said, that
lines. operator the up Anthony? have the open Let’s
